But the World Health Organization’s (WHO) green light means that countries without their own regulatory bodies, or a means of rigorously evaluating the effectiveness and safety of vaccines, can speed up their own approval processes and launch vaccination programs.
Concerns have been raised about the uneven distribution of vaccines as rich countries have purchased or signed contracts to purchase large quantities of people waiting for available doses or approvals.
“This is a very positive step towards ensuring global use of Covid-1 vaccines. But I would like to emphasize the need for even more global efforts to obtain adequate vaccine supplies to meet the needs of the priority population everywhere,” said Dr. , WHO Assistant Director for Access to Medicines and Health Products.
“The WHO and our partners are working day and night to evaluate other vaccines that have reached safety and efficacy standards. We encourage even more developers to come forward for review and evaluation. It is important to secure the critical supplies needed to serve all surrounding countries. The world and the epidemic stem. ”
The WHO team and independent experts reviewed quality data for the safety, effectiveness and risk-versus-benefit analysis of the Pfizer / Bioentech vaccine, the statement said.
“The review found that the vaccine met the required safety and efficacy criteria set by the WHO, and the advantages of using the vaccine to address potential risks to Covid-19,” he said.
A group of WHO vaccination experts will meet on January 5 to give policies and recommendations for vaccine use in the population. It will also help them establish cold supply chains, as the vaccine needs to be stored at 60-90 C.
When the Pfizer / Bioentech vaccine is first approved by the WHO, it is hoped that cheaper and easier distribution options will be available soon.
AstraZeneca has promised to give millions of doses to low- and middle-income countries and to deliver vaccines to those nations on a permanently profitable basis.
.
